Polyspecificity - An emerging trend in the development of clinical antibodies

Sandeep, .; Shinde, Suraj H.; Pande, Abhay H.

doi:10.1016/j.molimm.2023.02.005

Cited by 7 publications

(1 citation statement)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PsAb immunotherapy involves the use of bispecific, trispecific and tetraspecific monoclonal antibodies as a therapy for patients of multiple diseases including cancer, inflammation, neurodegenerative, infections, metabolic disorders, etc [187]. The most important benefit of the use of PsAb immunotherapy is the simultaneous blocking of multiple targets which stimulate multiple pathological pathways necessary for the disease progression.…”

Section: Psab-based Immunotherapymentioning

confidence: 99%

Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics

Sandeep,

Shinde,

Ahmed

et al. 2023

Immunology

Self Cite

View full text Add to dashboard Cite

The 21st‐century beginning remarked with the huge success of monospecific MAbs, however, in the last couple of years, polyspecific MAbs (PsAbs) have been an interesting topic and show promise of being biobetter than monospecific MAbs. Polyspecificity, in which a single antibody serves multiple specific target binding, has been hypothesized to contribute to the development of a highly effective antibody repertoire for immune defence. This polyspecific MAb trend represents an explosion that is gripping the whole pharmaceutical industry. This review is concerned with the current development and quality enforcement of PsAbs. All provided literature on monospecific MAbs and polyspecific MAbs (PsAbs) were searched using various electronic databases such as PubMed, Google Scholar, Web of Science, Elsevier, Springer, ACS, Google Patent and books via the keywords Antibody engineering, Polyspecific antibody, Conventional antibody, non‐conventional antibody, and Single domain antibody. In the literature, there are more than 100 different formats to construct PsAb by quadroma technology, chemical conjugation and genetic engineering. Till March 2023, nine PsAb have been approved around the world, and around 330 are in advanced developmental stages, showing the dominancy of PsAb in the growing health sector. Recent advancements in protein engineering techniques and the fusion of non‐conventional antibodies have made it possible to create complex PsAbs that demonstrate higher stability and enhanced potency. This marks the most significant achievement for cancer immunotherapy, in which PsAbs have immense promise. It is worth mentioning that seven out of the nine PsAbs have been approved as anti‐cancer therapy. As PsAbs continue to acquire prominence, they could pave the way for the development of novel immunotherapies for multiple diseases.

show abstract

Section: Psab-based Immunotherapymentioning

confidence: 99%